HealthDay News — For patients with resected stage IB-IIIA epidermal growth factor receptor ... in the osimertinib group; most events occurred after cessation of osimertinib (19 of 28 events ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate ...

Cibc World Markets Corp acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector Perform recommendation. Analyst Price Forecast Suggests 78.12% Upside As of ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery ...

He then served as a subject matter expert for combating terrorism on the vice president’s National Domestic Preparedness Review Group. In October 2001 ... for Infrastructure and Information Assurance ...

Molecular residual disease detection may help identify patients with EGFR-mutated NSCLC who could benefit from prolonged ...

In pN1 SLN group, the median DFS is not reached ... It demonstrated that atezolizumab significantly improved DFS in patients with stage II-IIIa NSCLC with Programmed death-ligand 1 (PDL1) expression ...

This group is referred to as the ‘Investigative Subcommittee ... will be made aware that a report was made about them alleging a violation of the Code. iiia. Reporters will not be anonymous to the ...

During four FDS procedures some thrombus formation was noted during operation that was completely resolved after the injection of a glycoprotein (GP) IIb/IIIa inhibitor ... was 0% in the ...